Eric Zijlstra
About
Eric Zijlstra is a scholar working on Endocrinology, Diabetes and Metabolism, Surgery and Pediatrics, Perinatology and Child Health.
According to data from OpenAlex, Eric Zijlstra has authored 39 papers receiving a total of 928 indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Endocrinology, Diabetes and Metabolism, 16 papers in Surgery and 7 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in Eric Zijlstra's work include Diabetes Management and Research (29 papers), Diabetes Treatment and Management (21 papers) and Pancreatic function and diabetes (16 papers). Eric Zijlstra is often cited by papers focused on Diabetes Management and Research (29 papers), Diabetes Treatment and Management (21 papers) and Pancreatic function and diabetes (16 papers). Eric Zijlstra collaborates with scholars based in Germany, Denmark and United States. Eric Zijlstra's co-authors include Tim Heise, Leszek Nosek, Leona Plum‐Mörschel, Lutz Heinemann, Hanne Haahr, Christoph Kapitza, Karsten Wassermann, Karsten Lyby, Thomas Först and Ulrike Hövelmann and has published in prestigious journals such as PLoS ONE, Diabetes Care and Diabetes.
In The Last Decade
Eric Zijlstra
36 papers receiving 886 citations
Peers
Eric Zijlstra
Julie Bukar United States
Samantha Koo-McCoy United States
İlgın Yıldırım Şimşir Türkiye
V. Lassmann‐Vague France
Payam Salehi United States
H. Gin France
Neda Rajamand Ekberg Sweden
Jia Zhou China
Nevin Oruç Türkiye
Citations per year, relative to Eric Zijlstra Eric Zijlstra (= 1×)
peers
Julie Bukar
Countries citing papers authored by Eric Zijlstra
Since
Specialization
Citations
This map shows the geographic impact of Eric Zijlstra's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eric Zijlstra with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eric Zijlstra more than expected).
Fields of papers citing papers by Eric Zijlstra
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Eric Zijlstra. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eric Zijlstra. The network helps show where Eric Zijlstra may publish in the future.
Co-authorship network of co-authors of Eric Zijlstra
This figure shows the co-authorship network connecting the top 25 collaborators of Eric Zijlstra. A scholar is included among the top collaborators of Eric Zijlstra based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eric Zijlstra. Eric Zijlstra is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Plum‐Mörschel, Leona, et al.. (2023). Noninvasive Continuous Glucose Monitoring With a Novel Wearable Dial Resonating Sensor: A Clinical Proof-of-Concept Study. Journal of Diabetes Science and Technology. 18(6). 1408–1415.
2.
Chen, Wei, Jia Lu, Leona Plum‐Mörschel, et al.. (2023). Pharmacokinetic and pharmacodynamic bioequivalence of Gan & Lee insulin analogues aspart (rapilin®), lispro (prandilin®) and glargine (basalin®) with EU ‐ und US‐sourced reference insulins. Diabetes Obesity and Metabolism. 25(12). 3817–3825.
3.
Leohr, Jennifer, Mary Anne Dellva, Elizabeth LaBell, et al.. (2023). Ultra rapid lispro (Lyumjev®) shortens time to recovery from hyperglycaemia compared to Humalog® in individuals with type 1 diabetes on continuous subcutaneous insulin infusion. Diabetes Obesity and Metabolism. 26(1). 215–223.
4.
Garhyan, Parag, Edward Pratt, Oliver Klein, et al.. (2022). Evaluation of Insulin Lispro Pharmacokinetics and Pharmacodynamics Over 10 Days of Continuous Insulin Infusion in People With Type 1 Diabetes. Journal of Diabetes Science and Technology. 17(2). 274–282.
5.
Leohr, Jennifer, Mary Anne Dellva, Elizabeth LaBell, et al.. (2020). Pharmacokinetic and Glucodynamic Responses of Ultra Rapid Lispro vs Lispro Across a Clinically Relevant Range of Subcutaneous Doses in Healthy Subjects. Clinical Therapeutics. 42(9). 1762–1777.e4.
6.
Heise, Tim, Helle Linnebjerg, David E. Coutant, et al.. (2020). Ultra rapid lispro lowers postprandial glucose and more closely matches normal physiological glucose response compared to other rapid insulin analogues: A phase 1 randomized, crossover study. Diabetes Obesity and Metabolism. 22(10). 1789–1798.
7.
Leohr, Jennifer, Mary Anne Dellva, David E. Coutant, et al.. (2020). Pharmacokinetics and Glucodynamics of Ultra Rapid Lispro (URLi) versus Humalog® (Lispro) in Patients with Type 2 Diabetes Mellitus: A Phase I Randomised, Crossover Study. Clinical Pharmacokinetics. 59(12). 1601–1610.
8.
Suico, Jeffrey G., Ulrike Hövelmann, Shuyu Zhang, et al.. (2020). Glucagon Administration by Nasal and Intramuscular Routes in Adults With Type 1 Diabetes During Insulin-Induced Hypoglycaemia: A Randomised, Open-Label, Crossover Study. Diabetes Therapy. 11(7). 1591–1603.
9.
Lyby, Karsten, et al.. (2019). The Effect of Food Intake on the Pharmacokinetics of Oral Basal Insulin: A Randomised Crossover Trial in Healthy Male Subjects. Clinical Pharmacokinetics. 58(11). 1497–1504.
10.
Lyby, Karsten, et al.. (2019). Efficacy and safety of oral basal insulin versus subcutaneous insulin glargine in type 2 diabetes: a randomised, double-blind, phase 2 trial. The Lancet Diabetes & Endocrinology. 7(3). 179–188.
11.
Andersen, Grit, et al.. (2019). 150-OR: BioChaperone Pramlintide Insulin (BCPramIns), a New Co-Formulation of Pramlintide (PRAM) and Human Insulin (INS), Improves Postprandial Blood Glucose (BG) vs. Both Separate Injections of PRAM+INS and Insulin Lispro (LIS) in Subjects with T1D. Diabetes. 68(Supplement_1).
12.
Moser, Othmar, Max L. Eckstein, Stephen C. Bain, et al.. (2018). Heart rate dynamics during cardio-pulmonary exercise testing are associated with glycemic control in individuals with type 1 diabetes. PLoS ONE. 13(4). e0194750–e0194750.
13.
Suico, Jeffrey G., Ulrike Hövelmann, Shuyu Zhang, et al.. (2018). Nasal Glucagon: Potentially Viable Alternative to Treat Insulin-Induced Hypoglycemia in Adults with Type 1 Diabetes. Canadian Journal of Diabetes. 42(5). S53–S53.
14.
Zijlstra, Eric, et al.. (2017). Impact of Injection Speed, Volume, and Site on Pain Sensation. Journal of Diabetes Science and Technology. 12(1). 163–168.
15.
Moser, Othmar, Max L. Eckstein, Stephen C. Bain, et al.. (2017). Poor glycaemic control is associated with reduced exercise performance and oxygen economy during cardio-pulmonary exercise testing in people with type 1 diabetes. Diabetology & Metabolic Syndrome. 9(1). 93–93.
16.
Heise, Tim, Ulrike Hövelmann, Eric Zijlstra, et al.. (2016). A Comparison of Pharmacokinetic and Pharmacodynamic Properties Between Faster-Acting Insulin Aspart and Insulin Aspart in Elderly Subjects with Type 1 Diabetes Mellitus. Drugs & Aging. 34(1). 29–38.
17.
Heise, Tim, et al.. (2016). Pharmacological properties of faster‐acting insulin aspart vs insulin aspart in patients with type 1 diabetes receiving continuous subcutaneous insulin infusion: A randomized, double‐blind, crossover trial. Diabetes Obesity and Metabolism. 19(2). 208–215.
18.
Heise, Tim, Kirstine L. Stender-Petersen, Ulrike Hövelmann, et al.. (2016). Pharmacokinetic and Pharmacodynamic Properties of Faster-Acting Insulin Aspart versus Insulin Aspart Across a Clinically Relevant Dose Range in Subjects with Type 1 Diabetes Mellitus. Clinical Pharmacokinetics. 56(6). 649–660.
19.
Kapitza, Christoph, et al.. (2010). Oral Insulin: A Comparison With Subcutaneous Regular Human Insulin in Patients With Type 2 Diabetes. Diabetes Care. 33(6). 1288–1290.
20.
Kapitza, Christoph, et al.. (2010). Effect of Three Different Injection Sites on the Pharmacokinetics of the Once-Daily Human GLP-1 Analogue Liraglutide. The Journal of Clinical Pharmacology. 51(6). 951–955.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Julie Bukar Breakdown of academic impact, for papers by Samantha Koo-McCoy Breakdown of academic impact, for papers by İlgın Yıldırım Şimşir Breakdown of academic impact, for papers by V. Lassmann‐Vague Breakdown of academic impact, for papers by Payam Salehi Breakdown of academic impact, for papers by H. Gin Breakdown of academic impact, for papers by Neda Rajamand Ekberg Breakdown of academic impact, for papers by Jia Zhou Breakdown of academic impact, for papers by Nevin Oruç